Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

被引：21
|
作者：
Zobniw, Chrystia M. [1 ]
Causebrook, Alanna [2 ]
Fong, Mei Ka [1 ]
机构：
[1] Roswell Pk Canc Inst, Dept Pharm, Elm & Carlton St, Buffalo, NY 14263 USA
[2] Erie Coll Osteopath Med, Sch Pharm, Erie, PA USA
来源：
RESEARCH AND REPORTS IN UROLOGY | 2014年 / 6卷
关键词：
glucocorticoid receptor; CYP17; pipeline; enzalutamide; sipuleucel-T; drug resistance; radium-223; dichloride;
D O I：
10.2147/RRU.S29003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
引用
收藏
页码：97 / 105
页数：9
相关论文
共 50 条
  • [31] Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
    Han, Christopher Sejong
    Patel, Rutveej
    Kim, Isaac Yi
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (06) : 967 - 975
  • [32] Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Federico, Piera
    Daniele, Bruno
    Morelli, Franco
    Bellelli, Teresa
    Ferro, Matteo
    De Placido, Sabino
    Buonerba, Carlo
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 874 - 879
  • [33] Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
    Stein, Cy A.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : 407 - 409
  • [34] Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Chopra, Akhil
    Haaland, Benjamin
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Abiraterone for Treatment of Metastatic Castration-resistant Prostate Cancer: a Systematic Review and Meta-analysis
    Zhou, Zhi-Rui
    Liu, Shi-Xin
    Zhang, Tian-Song
    Xia, Jun
    Li, Bo
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) : 1313 - 1320
  • [36] Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
    Rauch, Simon
    Fong, Dominic
    Morra, Elisa
    Maines, Francesca
    Caffo, Orazio
    Spizzo, Gilbert
    PROSTATE INTERNATIONAL, 2016, 4 (02) : 54 - 55
  • [37] Effects of abiraterone in Japanese men with metastatic castration-resistant prostate cancer after enzalutamide treatment
    Iio, Hiroyuki
    Shiozaki, Keito
    Ozaki, Kisuke
    Tsujioka, Takuya
    Nishimura, Kennichi
    Fujikata, Shirou
    Tanimoto, Shuuji
    Okamoto, Kenjirou
    Yamashi, Sadamu
    Kan, Masaharu
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Beyond abiraterone New hormonal therapies for metastatic castration-resistant prostate cancer
    Pinto, Alvaro
    CANCER BIOLOGY & THERAPY, 2014, 15 (02) : 149 - 155
  • [39] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
  • [40] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
12345